US approves trials of new cancer drug delivery procedure
By Lee I-chia / Staff reporter
The National Health Research Institutes (NHRI) yesterday said that a new cancer drug delivery system DBPR115 developed by an affiliated institute has obtained approval from the US Food and Drug Administration as an investigational new drug that can enter phase 1 clinical trials.
The NHRI said that the delivery system was developed by researchers at its Institute of Biotechnology and Pharmaceutical Research (IBPR), supported by the Ministry of Economic Affairs’ Department of Industrial Technology, under the government’s technology development program.
IBPR Director Chang Jang-yang (張俊彥) said that drugs can be used to treat cancer cells, but high doses often cause severe side effects, as they can also damage normal cells.
公示！福建23位干部拟提任厅级领导职务 sina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.cn Daily Mail and Mail on Sunday newspapers.